These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 9620341)

  • 1. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.
    Allen MI; Deslauriers M; Andrews CW; Tipples GA; Walters KA; Tyrrell DL; Brown N; Condreay LD
    Hepatology; 1998 Jun; 27(6):1670-7. PubMed ID: 9620341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
    Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection.
    Ono-Nita SK; Kato N; Shiratori Y; Masaki T; Lan KH; Carrilho FJ; Omata M
    Hepatology; 1999 Mar; 29(3):939-45. PubMed ID: 10051501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B.
    Ogata N; Fujii K; Takigawa S; Nomoto M; Ichida T; Asakura H
    J Med Virol; 1999 Nov; 59(3):270-6. PubMed ID: 10502255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo.
    Tipples GA; Ma MM; Fischer KP; Bain VG; Kneteman NM; Tyrrell DL
    Hepatology; 1996 Sep; 24(3):714-7. PubMed ID: 8781348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of YMDD mutations in hepatitis B virus DNA with the use of allele specific polymerase chain reaction].
    Pichkovskaia VA; Fevraleva IS; Ibragimova MM; Solov'eva TI; Drel' PE; Sudarikov AB
    Mol Gen Mikrobiol Virusol; 2004; (1):27-9. PubMed ID: 15025001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
    Pollicino T; Isgrò G; Di Stefano R; Ferraro D; Maimone S; Brancatelli S; Squadrito G; Di Marco V; Craxì A; Raimondo G
    Antivir Ther; 2009; 14(5):649-54. PubMed ID: 19704167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.
    Yeh CT; Chien RN; Chu CM; Liaw YF
    Hepatology; 2000 Jun; 31(6):1318-26. PubMed ID: 10827158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
    Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Kobayashi M; Ikeda K; Miyakawa Y; Kumada H
    J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN; Chauhan R; Das BC; Sarin SK
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
    Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
    Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
    J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCR restriction fragment length polymorphism in detection of YMDD variants of viral polymerase in hepatitis B virus patients treated with lamivudine.
    Yang DH; Liang WF; Xie YJ; Zhao NF; Fan J
    Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):232-7. PubMed ID: 14612274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No benefit to continue lamivudine therapy after emergence of YMDD mutations.
    Liaw YF; Chien RN; Yeh CT
    Antivir Ther; 2004 Apr; 9(2):257-62. PubMed ID: 15134188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.
    Kim JW; Lee HS; Woo GH; Yoon JH; Jang JJ; Chi JG; Kim CY
    Clin Infect Dis; 2001 Aug; 33(3):403-5. PubMed ID: 11438912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.